Ciloa is dedicated to the development of new high-potential therapies through its bio-drug development technology using exosomes.
Thanks to its technology, the most advanced in the field of recombinant exosomes, Ciloa brings new solutions to work with targets currently called “challenging” or “undruggable”.
The first application aims to develop therapeutic antibodies to fight cancer, and also infectious, cardiac, genetic, immune and neurological diseases.
Ciloa’s exosomes unlock 4 bottlenecks in the development of therapeutic antibodies targeting challenging membrane antigens : perfect antigen, immunization, hit screening and lead characterization.
The second application concerns the development of a new generation of vaccines without viruses or adjuvants.
To validate this application, Ciloa is actively working on 2 vaccine candidates against Chikungunya and Zika viruses, awarded by 2 national grants.
The third application aims to design therapeutic vectors without viruses. Exosomes have the ability to cross all biological barriers in the body and are the main mediators of the stem cell properties.
Thus, therapeutic exosomes would allow to cure challenging diseases, including neurological ones.